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Abstract
Introduction: Non-small cell lung cancer (NSCLC) has become the leading cause of cancer-related deaths in Poland.  Follow-up of 
patients with NSCLC is aimed at early detection of local recurrence, metastatic process,  treatment-related complications or second 
primary lung cancer. We investigated the diagnostic accuracy of FDG-PET-CT in the detection of recurrence of NSCLC after treatment. 
Material and methods: Seventy-two NSCLC patients (19 females, 56 males), stage I to IV, who had undergone surgery and/ 
/or radiation therapy, occasionally associated with chemotherapy, were retrospectively included in our study. 
Chest radiographs and thoracic computed tomography (CT) were performed to localize the  abnormality prior to PET-CT. All 
the patients underwent  CT and PET-CT in the period from January 2008 until January 2012. All PET images were  interpreted 
in conjunction with thoracic CT. PET-CT and CT diagnoses were correlated with pathological diagnoses.
Results: Forty-five patients had recurrent tumour. Tumour recurrence was observed more often in men than in women and 
also in case of neoplastic cell emboli in lymphatic or blood vessels. In three patients second primary lung cancer was dia-
gnosed. False positive diagnosis of relapse based on PET-CT was obtained in 4 patients, mainly due to inflammatory lesions. 
The accuracy of PET-CT for diagnosis of recurrence  was 94.4% (95% CI 91; 100). 
Conclusions: FDG PET-CT was the best method  to differentiate recurrent bronchogenic carcinoma from inflammatory 
lesions, especially at post-therapeutic sites. It has been shown that PET-CT is more accurate method than CT in recurrent 
NSCLC. PET-CT results had a further impact on the clinical management and treatment planning.
Key words: lung cancer, recurrent NSCLC, PET-CT 
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Streszczenie
Wstęp: Niedrobnokomórkowy rak płuca (NDRP) jest wiodącą przyczyną zgonów spowodowanych chorobami nowotworo-
wymi w Polsce. Kontrola pacjentów po leczeniu raka płuca ma na celu wczesne wykrycie wznowy miejscowej, rozsiewu 
procesu nowotworowego, powikłań po leczeniu. Istotne jest też wczesne wykrycie kolejnego nowotworu. 
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W pracy badano przydatność metody PET-CT w ocenie nawrotu NDRP po leczeniu. 
Materiał i metody: Do badania włączono retrospektywnie 72 pacjentów (19 kobiet, 56 mężczyzn) z NDRP w stopniu zaawan-
sowania I–IV poddanych leczeniu operacyjnemu i/lub radioterapii. Niektórzy z nich byli poddani chemioterapii. Radiogram 
klatki piersiowej i/lub badanie TK lokalizowały zmiany podejrzane o wznowę przed badaniem PET-CT. Wszyscy pacjenci mieli 
wykonane badanie TK i PET-CT pomiędzy styczniem 2008 roku a styczniem 2012 roku. Badania PET-CT interpretowano 
w zestawieniu z badaniami TK. Następnie wyniki zestawiono z badaniem histopatologicznym. 
Wyniki: Wśród badanych pacjentów u 45 potwierdzono nawrót raka płuca, u 3 obecność drugiego raka płuca. Wznowa 
występowała częściej u mężczyzn niż u kobiet oraz u chorych, u których stwierdzono zatory z komórek nowotworowych 
w naczyniach guza. U 4 chorych rozpoznanie wznowy na podstawie PET-CT nie zostało potwierdzone podczas dalszej dia-
gnostyki. Dotyczyło to przede wszystkim chorych, u których ostatecznie rozpoznano zmiany o etiologii zapalnej. Dokładność 
badania PET-CT u pacjentów badanych pod kątem nawrotu raka płuca wyniosła 94,4% (95% CI 91; 100). 
Wnioski: FDG PET-CT pozwoliło u większości pacjentów odróżnić zmiany nowotworowe od zmian zapalnych po przebytym 
leczeniu. W pracy wykazano, że PET-CT jest bardziej dokładne od metody TK w ocenie nawrotu raka płuca. Badanie PET-CT 
ma istotne znaczenie w postępowaniu klinicznym i planowaniu leczenia.
 Słowa kluczowe: rak płuca, nawrót raka płuca, PET-CT 
Pneumonol. Alergol. Pol. 2013; 81: 215–220 
Introduction
Non-small cell lung cancer (NSCLC) remains 
a major oncological challenge in most countries. 
Surgical treatment is combined with best pro-
gnosis and the possibility to  cure of the disease; 
however, the tumour stage at diagnosis precludes 
resectability in most patients. These patients are 
submitted to chemotherapy, radiation therapy, or a 
combination of the two therapeutic modalities. Fol-
low-up after treatment permits early detection of: 
disease relapse, another primary lung tumour, or 
treatment-related complications. Early and correct 
diagnosis of disease recurrence leads to appropriate 
therapy and gives a chance for longer survival. 
Detection of local relapse or the presence of single 
distant metastasis results in implementation of 
further therapeutic methods such as chemotherapy, 
radiotherapy, or a repeated surgical procedure.
We investigated the diagnostic accuracy of 
FDG-PET-CT in the detection of recurrence of 
NSCLC after treatment.  
Material and methods
The study population included 72 patients 
with previously treated NSCLC, who were ad-
mitted to the National Tuberculosis and Lung 
Diseases Research Institute  between January 
2008 and January 2012 due to suspected disease 
recurrence (possibility of local recurrence or su-
spicion of distant metastases).  Relapse of NSCLC 
was suspected based on clinical picture, results 
of bronchoscopic investigation, chest X-ray, and/ 
/or computed tomography. In 69 of 72 analysed 
patients, PET-CT was performed in radiological 
facilities of the Euromedic Company in Warsaw 
(centre A), using the GE Discovery STE device. In 
three patients, PET-CT scanning was performed at 
the Department of Nuclear Medicine of the Medical 
University of Warsaw, using a Siemens Biograph 
Truepoint64 device (centre B).
All patients were intravenously administered 
18FDG radiopharmaceutical as a part of the PET-CT 
scanning procedure. The activity of the radiophar-
maceutical applied in centre A was 320–400 MBq, 
and 250-450 MBq in centre B. Radiopharmaceutical 
was administered 45 minutes before PET-CT scan-
ning in centre A and 60 minutes before PET-CT 
procedure in centre B. 
Marker uptake was measured semiquantitati-
vely and expressed as standardised uptake values 
(SUV), which represent corrected activity of the 
radio marker (mCi) per millilitre of tissue confined 
to the area of interest [mCi/ml] and/or expressed 
as the given activity of the radio marker (mCi) per 
lean body mass (g) in centre A or per total body 
mass (g) in centre B [mCi/g].
The adopted threshold SUV value for benign 
lesions was equal to or less than 2.5, as described 
in literature. 
Chest CT scans were taken at the National 
Tuberculosis and Lung Diseases Research Institute 
using a Siemens 16-detector-row Somatom Sen-
sation device. Spiral CT scanning was performed 
in all patients included in the study. Dimensions 
of recurring lung tumours were measured on CT 
scans along the longer axis of the lesion. Nodal 
recurrences were also evaluated on CT scans, 
using the dimension along the shorter axis, if two 
dimensions could be measured. 
Average time interval between CT and PET-CT 
scanning was four weeks.
Histopathological diagnosis was made in 
majority of patients based on evaluation of  surgi-
cal specimens and/or  samples obtained through 
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presence of tumour cell embolisation of lymphatic 
(L feature) or blood vessels (V feature) in selected 
cases.
Results
Patients with disease recurrence
PET-CT revealed disease recurrence in 49/72 
patients, of which in 45/72  true lung cancer relapse 
was diagnosed (Tab. 1). Cancer recurrences were 
confirmed by histopathology and/or by clinical 
observation. The mean age of the patients who 
relapsed was 66.5 years (range 48–86 years),  men 
constituted 70.5% of the subjects with disease 
recurrence (31/45). 
Before onset of therapy, clinical staging 
(cTNM classification) was performed in 64.4% 
of the patients (29/45), revealing stage I disease 
in 2/45 patients, stage II — in 9/45, stage III — in 
15/45, and stage IV in 3/45 patients.
Adenocarcinoma was identified in 40% of 
patients (18/45), squamous cell carcinoma in 56% 
(25/45), pleomorphic carcinoma in 2% (1/45), and 
adenosquamous carcinoma in 2% (1/45). Com-
pleteness of resection and angioinvasion criteria 
(RLV features) were  evaluated in 64.4% of pa-
tients (29/45). Complete resection was confirmed 
in 28/29 patients. Signs of invasion of lymphatic 
vessels were found in 26/29.  Invasion of blood 
vessels was observed in 26/29 patients.  Degree 
of tumour differentiation  was assessed in 42/45 
patients, including 1/42 case of well-differentiated 
carcinoma (G1), 30/42 cases of moderately differen-
tiated carcinoma (G2), and 11/42 cases of poorly 
differentiated tumour (G3). 
The average dimension of a recurrent lung 
tumour was 31 mm. Pulmonary recurrences were 
identified in 35 patients, of which one case turned 
out to be a false positive finding. In 10 patients, 
recurrences were found among post-radiation 
lesions; differential diagnostics in these cases 
concerned treatment-related changes and focal 
disease relapse. Post-radiation lesion was described 
as tumour relapse in one patient (false positive 
result). Mean SUV for pulmonary recurrence was 
6.9 (1.9–28.5).
Disease relapse in lymph nodes was found 
in 19 patients, of which three cases turned out to 
be false positive findings. Recurrent tumour foci 
were found in normally sized lymph nodes in two 
patients. Mean SUV for nodal recurrence was 6.0 
(2.0–22.3). 
Extrathoracic metastases were found in six 
patients. These included metastases to the skeletal 
system, adrenal glands, liver, and spleen.
Table 1.  Clinical characteristics of 45 patients with recur-
rent NSCLC
Sex Women 14
 Men 31
Age Mean 66,5
 Range 48–86
Histological type Adenocarcinoma 18
 Squamus 25
 Carcinoma pleomorphicum 1
 Carcinoma 
adenosquamosum
1
Extension of disease 
— 29 patients
I 2
 II 9
 III 15
 IV 3
G status  
— 42 patients
1 1
 2 30
 3 11
R status  
— 29 patients
R0 28
 R1 1
 R2 0
L status  
— 29 patients
L0 3
 L1 26
 L2 0
V status  
— 29 patients
V0 3
 V1 26
 V2 0
Therapy Surgery 33
 Surgery  
and radiochemotherapy 
10
 Radiation therapy and/or 
chemotherapy
2
 
transthoracic biopsy. In 5 patients the diagnosis 
was obtained from bronchial biopsy specimens, 
in two — from bronchoalveolar lavage cytology. 
For tumour description and classification, 
2004 WHO criteria were applied. Histological 
type, grading (degree of tumour differentiation, G 
feature), and completeness of resection (R feature) 
were assessed, alongside with investigation of the 
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Table 2.  Clinical characteristics of 24 patients with did 
not confirm recurrent NSCLC 
Sex Women 19
 Men 5
Age Mean 64,7
 Range 37–82
Histological type Adenocarcinoma 6
 Squamus 10
 Large cell carcinoma 1
 Neuroendocrine tumor 3
 Carcinoma pleomorphicum 1
 Non-small carcinoma 3
Extension of disease 
— 16 patients
I 0
 II 10
 III 6
 IV 0
G status  
— 24 patients
1 0
 2 10
 3 14
R status  
— 15 patients
R0 14
 R1 1
 R2 0
L status  
— 15 patients
L0 8
 L1 7
 L2 0
V status  
— 15 patients
V0 6
 V1 9
 V2 0
R0 — no residual tumor; R1 — microscopic residual tumor; R2 — macroscopic 
residual tumor; L0 — no lymphatic vessel invasion; L1 — microscopic lymphatic 
vessel invasion; L2 — macroscopic lymphatic vessel invasion; V0 — no venous 
invasion; V1 — microscopic venous invasion; V2 — macroscopic venous invasion 
In four of the analysed patients, PET-CT exa-
mination permitted precise delineation of tumour 
recurrence among the surrounding structures.
In some patients surgical resection of recurrent 
tumours could be performed, whereas others were 
irradiated or received chemotherapy. 
Patients with identified second primary 
tumour
Histopathological examination confirmed the 
presence of another primary lung cancer in three 
of the 72 analysed patients. Two of them were 
diagnosed with squamous cell carcinoma, and the 
second primary tumour was of adenocarcinoma 
type. In another patient, the first diagnosed tumour 
showed signs of glandular differentiation (adeno-
carcinoma), whereas the second one turned out to 
be squamous cell carcinoma.
Patients with no signs of cancer recurrence
No signs of recurrence were found in 33.3% of 
patients (24/72) in the studied population (Tab. 2). 
The mean age in this group was 64.7 years (37–82 
years), and 79.2% of them were women (19/24). In 
66.6% of these subjects (16/24) cTNM was assessed 
before therapy onset. There were no cases of stage 
I or stage IV disease, 10/16 patients were diagnosed 
stage II, and 6/16 patients — stage III.
Histopathological assessment of tumours reve-
aled 25% of cases of adenocarcinoma (6/24), 41.6% of 
cases of squamous cell carcinoma (10/24), 4% of large 
cell carcinoma (1/24), and 12.5 % of cases of neuro-
endocrine tumours (3/24); the latter group included 
large cell neuroendocrine carcinoma in two patients, 
and multiple foci of typical and atypical carcinoid 
as well as the so-called tumorlets. In 12.5% of cases 
(3/24) the tumour was described as non-small cell 
cancer, not otherwise specified (NSCLC, NOS), and 
in 4% of cases (1/24) the diagnosis of pleomorphic 
carcinoma with no further specification was made. 
The RLV features were assessed in 62.5% of cases 
(15/24). Complete resection was confirmed in 14/15 
patients. Invasion of lymphatic vessels was found 
in 7/15 cases. Involvement of blood vessels was 
identified in 9/15 patients. Assessment of tumour dif-
ferentiation grade  was performed in 21/24 patients, 
revealing moderately differentiated tumours (G2) 
in 10/21 subjects, and poorly differentiated cancer 
(G3) in 11/21persons. There were no cases of well-
differentiated carcinoma (G1).
Standardised uptake values (SUV) were po-
sitive (>2.5) in 12.5% of patients (3/24); Mean 
SUV was 7.9. All of them had false positive results 
of PET-CT investigation, i.e. disease relapse was 
finally not confirmed in these subjects. For the 
remaining patients, the lesions were described as 
showing no marker uptake.
In one of the patients, the SUV for a relapse
-suspected lesion was 15.0, and increased to 17.5 
min in the delayed phase investigation. Following 
PET-CT investigation, cancer recurrence was dia-
gnosed, which, however, was not confirmed in 
a sample obtained through transthoracic biopsy. Fol-
low-up CT performed three months after PET-CT 
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showed regression of lung consolidations, which 
were thus interpreted as  inflammatory lesions (Fig. 
1–3). In two other patients, disease recurrence was 
suspected based on positive PET-CT  of enlarged 
lymph nodes, which then decreased in size in 
follow-up investigations. 
Diagnostic accuracy for cancer recurrence 
detection was 94.4% in the analysed patient popu-
lation (95% CI: 91–100). Identification of another 
primary lung cancer in 3/72 patients was also 
interpreted as a true positive result.
Discussion
Patients treated for NSCLC should be follo-
wed-up radiologically in order to detect potential 
signs of disease progression [1]. In the postope-
rative period chest X-ray is aimed at assessing 
pulmonary pathology secondary to operation. The 
persistence of fluid in the post-operation chamber 
for over 3–6 months in the patients treated with 
pneumonectomy suggests the presence of a bron-
chopleural fistula. 
Disease recurrence may be local (i.e. in the 
area previously operated on), regional (in regional 
lymph nodes), or distant. Local or regional recu-
rrences occur mainly in the bronchi and lymph 
nodes ipsilateral to the primary tumour; these 
sites also include supraclavicular lymph nodes 
[2]. Tumours remaining within the area of the sur-
gical margins are described as local recurrences, 
whereas lesions located outside these margins 
A
B
Figure 1. 58-year-old man with advanced carcinoma after radiation 
therapy. Abnormal area of consolidation. Suspected recurrent tumor. 
CT obtained 8 months after completion of radiation therapy 
Figure 2. The same patient. PET-CT scan showed increased FDG 
uptake in the area of fibrosis. Transthoracic biopsy did not confirm 
reccurence
Figure 3. Follow up chest CT taken 3 months later. Abnormal area 
of consolidation got smaller
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represent distant metastases. The risk of disease 
recurrence is multifactorial and remains not com-
pletely elucidated [3]. Recognised risk factors for 
lung cancer relapse include histological tumour 
type, disease stage at treatment onset, and surgery-
-related issues, such as completeness of resection, 
and involvement of lymphatic or blood vessels 
identified microscopically in surgical specimens. 
In the examined group of patients lung cancer 
relapse was observed more often in men than in 
women and in case of the presence of neoplastic 
cell emboli in lymphatic or blood vessels.
Planning of radiological follow-up depends 
on many issues, including tumor histopathology, 
concomitant diseases, reported symptoms of the 
disease, and patient’s age. If clinical findings suggest 
the presence of extrathoracic metastases, the patient 
should be remitted for radiological assessment.  An 
important piece of information, which should be 
emphasised in the referral formulary for radiologi-
cal investigation, is whether the clinician requests 
a routine follow-up computed tomography scanning 
or if the investigation is carried on due to clinical su-
spicion of relapse or treatment related complications. 
Adenocarcinoma is the type of lung cancer 
with the greatest tendency for local recurrences 
or distant metastases [4]. Both squamous cell 
carcinoma and adenocarcinoma give more often 
distant metastases than locoregional recurren-
ces [5]. Large cell carcinoma also has a strong 
tendency to recur, whereas well-differentiated 
adenocarcinoma with lepidic growth type very 
rarely recurs locally.
There are certain limitations to the utility of 
computed tomography in the assessment of can-
cer recurrence [6]. Nevertheless, many reports in 
literature suggest that even conventional radiolo-
gical investigations can disclose the presence of 
cancer recurrences [7, 8]. The role of computed 
tomography remains controversial as this mo-
dality cannot differentiate between nonspecific 
lesions secondary to treatment and true cancer 
relapses [9]. Combined PET-CT is an impor-
tant tool in the assessment of cancer recurrence 
[10, 11], due to its high sensitivity. The false 
positive rate reported by Shon et al. six months 
after completed oncological treatment, was only 
8%  [12]. The threshold of lesion size described on 
CT scans remains controversial since it is known 
that normally sized lymph nodes may contain 
cancer metastases, whereas enlarged nodes can 
be reactively changed [13].
Combined PET-CT analysis is used for precise 
determination of the area to be irradiated [14] as 
well as for the assessment of indications for che-
motherapy in patients with multiregional disease 
relapse.
The probability of relapse is related to base-
line disease stage, including T and N descriptors. 
Tumours larger than 5 cm in maximal dimension 
recur more often than lesions of 3–5 cm. Recur-
rence within thoracic wall is more often observed 
after treatment of large tumours. Higher T stage 
also correlates with more frequent nodal recur-
rences [4, 5].
Distant metastases are found more often than 
local recurrences of NSCLC. The coexistence of 
locoregional and distant recurrences can be iden-
tified in approximately 20% of patients [2]. The 
risk of recurrence depends also on the applied 
treatment modality. Cancer treated by radiothera-
py can recur outside the irradiated area. A surgi-
cal approach limited to segmentectomy without 
lymphadenectomy bears a high risk of disease 
recurrence [15].
Differential diagnostics of treatment-related 
lesions (after surgery or radiotherapy) and true 
tumour recurrent foci are of the utmost importance. 
Post-radiation necrosis may present radiologically as 
a cavitated lesion, appearing in any lung area from 
one to seven years after treatment, and may raise 
a strong suspicion of metastasis [16]. False positive 
diagnosis of cancer relapse was diagnosed with PET
-CT in one of our patients, who received radiotherapy. 
Locoregional or distant recurrences are usu-
ally irradiated or treated with chemotherapy, and 
less often operated on, which depends on lung 
reserve among others [1]. Moreover, 1–4% of 
patients can also develop another primary lung 
cancer [17].
Radiological follow-up after lung cancer 
treatment is carried out in most cases for five 
years after therapy completion, as disease recu-
rrence is most often observed during this period. 
Chest X-ray remains an important investigation; 
however, many cases of disease relapse occur 
outside of the thorax [1]. Chest X-ray is the ba-
sic follow-up investigation, and CT should be 
performed in case of chest X-ray pathology  or 
clinical suspicion of relapse [6]. Some authors 
suggest that CT should be performed once a year, 
whereas in some centres chest X-ray is performed 
every four months during the first two years after 
treatment completion, complemented by CT 
once a year, in order to detect disease recurrence 
early [17]. Combined PET-CT permits differen-
tiation between cancer recurrence and lesions 
secondary to surgery. This diagnostic modality 
is believed to be more sensitive than compu-
ted tomography alone (sensitivity 97–100%, 
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specificity 62–100%). False positive results of 
PET-CT investigation are related to the presen-
ce of inflammatory lesions, particularly in the 
irradiated area. Therefore, PET-CT scanning is 
recommended not earlier than 4–5 months after 
completion of radiotherapy.
Conclusions
1. In the presented study combined PET-CT was 
a diagnostic modality of high accuracy in reco-
gnizing NSCLC relapse. The correct diagnosis 
of relapse or second primary tumor was made 
in 45/49 patients. Increased radio-marker 
uptake in non-neoplastic tissue was observed 
in 4/49 patients only.
2. Preoperative clinical staging according to TNM 
revealed a predominance of stage III disease 
in patients with confirmed tumour recurrence 
after treatment, whereas stage II was diagnosed 
in most patients who did not develop recur-
rences.
3. Tumour recurrence was observed more often 
in men than in women.
4. Tumour cell emboli in lymphatic or blood 
vessels were found more often in surgical 
specimens of tumours that relapsed  than in 
those that didn’t.
5. Combined PET-CT scanning permitted preci-
se delineation of tumour recurrence focus in 
relation to surrounding structures.
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